Naltrexone is typically administered to those who have a history of substance abuse, namely opiates or alcohol. The drug works to block the intensity of the drugs, so people are less likely to associate them with euphoria or pain relief. Because drug use in this country is still so stigmatized, it’s difficult to separate public[…]
A Controversial API with Plenty of Promise: Naltrexone
Anti-Obesity Product, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: Obesity Sep 14, 2018
Liraglutide FDA Approval Brings First Ever Injectable Weight Loss Drug
Anti-Diabetic, Anti-Obesity Product, FDA Approved 2014 Tags: LiraglutideUnited States Jan 26, 2015
The close of 2014 brought exciting news for Novo Nordisk’s innovative weight loss drug Saxenda. The Liraglutide FDA approval is the first of its kind as it’s the only available injectable treatment for obesity. The FDA overwhelmingly gave a nod to this easy to use form of Liraglutide as a safe and effectual option for[…]
FDA Approves Contrave – A Naltrexone Hydrochloride and Bupropion Hydrochloride Drug Combo
Anti-Obesity Product, Drug Research & Development API, FDA Approved 2014, OTC and Compounding Product Tags: BMIhigh blood pressure Sep 12, 2014
On September 10, 2014, The U.S. Food and Drug Administration (US FDA) approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) for anti-obesity treatments in combination with a reduced-calorie diet and exercise. Contrave is distributed by Takeda Pharmaceuticals America Inc. of Deerfield, Illinois for Orexigen Therapeutics, Inc. of La Jolla, California. The FDA approved the[…]
Topiramate Approved as Antiepileptic Drug
Anti-Migraine, Anti-Obesity Product, FDA Approved 2014 Tags: Annual MeetingepilepsyTopiramate Mar 14, 2014
On March 11, 2014 the FDA approved Topiramate, marketed as Qudexy™ XR by Upsher-Smith Laboratories, for the treatment of partial-onset seizures (POS) or primary generalized tonic-clonic seizures in patients 10+ years of age. It is also approved as adjunctive therapy in patients 2+ years of age for the aforementioned seizures, and seizures associated with Lennox-Gastaut[…]
Topiramate Works for Patients with Epilepsy and Migraines
Anti-Migraine, Anti-Obesity Product, Drug Research & Development API, Patent Expiration 2015 Tags: epilepsymigrainesTopiramate Aug 07, 2012
Topiramate CAS# 97240-79-4, is also known as the brand name medication Topamax. Marketed by Janssen, Topamax has a patent expiration of October 13, 2015. As an effectual and reliable medication to treat patients with both epilepsy and migraines, topiramate is known for it’s effectiveness as monotherapy or adjunctive therapy for the treatment of epilepsy. Tablets[…]
Lorcaserin Approved as the First Weight Loss Drug in over a Decade
Anti-Obesity Product, Drug Research & Development API Tags: BMIlorcaserin Jul 02, 2012
The dramatic approval of Lorcaserin, now known by the trade name Belviq, was announced on June 27, 2012. Lorcaserin, CAS# 846589-98-8, is the first drug to be approved for weight loss in over twelve years. This announcement, made by representatives from both Easai and Arena Pharmaceuticals was a welcome one for researchers, patients and practitioners[…]
Is Lorcaserin the Next Weight Loss Drug?
Anti-Obesity Product, Drug Research & Development API, NDA Tags: BMIlorcaserin Feb 21, 2012
Intended for weight management, including weight loss and maintenance of weight loss, lorcaserin is poised to become the next weight loss drug. Lorcaserin is aimed at clinically obese patients, or patients with a Body Mass Index, or BMI, >30, or patients who are overweight (BMI >27) and have at least one weight related co-morbid condition.[…]
LGM Pharma Supplies Ingredients for Several Anti-Obesity Drugs
Anti-Migraine, Anti-Obesity Product, Bulk Active Ingredient, Compounding API, Drug Research & Development API Tags: Drug AdministrationlorcaserinObesityTopiramate Aug 31, 2010
LGM Pharma supplies Topiramate, Bupropion, Naltrexone and Lorcaserin – Active Pharmaceutical Ingredients (APIs) used to treat obesity.
